- Previous Close
0.9488 - Open
0.9500 - Bid 0.6776 x 200
- Ask 1.2300 x 200
- Day's Range
0.9220 - 0.9747 - 52 Week Range
0.6900 - 1.6000 - Volume
133,272 - Avg. Volume
233,208 - Market Cap (intraday)
56.256M - Beta (5Y Monthly) 1.80
- PE Ratio (TTM)
-- - EPS (TTM)
-1.4300 - Earnings Date Mar 18, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.
www.kronosbio.comRecent News: KRON
View More
Performance Overview: KRON
Trailing total returns as of 3/18/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KRON
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KRON
View MoreValuation Measures
Market Cap
57.32M
Enterprise Value
-41.74M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.74
Price/Book (mrq)
0.52
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-25.13%
Return on Equity (ttm)
-59.08%
Revenue (ttm)
9.86M
Net Income Avi to Common (ttm)
-85.59M
Diluted EPS (ttm)
-1.4300
Balance Sheet and Cash Flow
Total Cash (mrq)
124.86M
Total Debt/Equity (mrq)
23.22%
Levered Free Cash Flow (ttm)
-39.43M
Research Analysis: KRON
View MoreCompany Insights: KRON
KRON does not have Company Insights